Update: 09.03.2021
Last week: 8 week 2022 (21.02.2022 - 27.02.2022)
Last full month: Jan 2021
| Time period | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat.Vol, Change |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | |||||||||
| WoW | 2 881 | -8.5% | 58.6% | 1.1 | 1 291 824 | -9.5% | 84.3% | 0.5 | -10.3% |
| MoM | 9 905 | 26.3% | 51.5% | 5.7 | 4 344 704 | 26.7% | 79.8% | 4 | 12.3% |
| YTD | 20 674 | 2.4% | 53.8% | -5.1 | 9 181 650 | 29.7% | 81.5% | 0.1 | 12.1% |
| MAT | 118 097 | -22.4% | 54.8% | -6.8 | 47 714 967 | 2.7% | 80.3% | -0.8 | -12.8% |
| CAPSICAM | |||||||||
| WoW | 43 966 | -5.0% | 3.7% | -0.1 | 18 103 082 | -4.3% | 3.8% | -0.1 | -2.4% |
| MoM | 197 048 | -7.4% | 3.9% | -0.6 | 80 797 216 | -6.6% | 4.1% | -0.6 | 7.0% |
| YTD | 361 990 | -11.9% | 7.5% | -0.4 | 148 259 340 | -14.4% | 7.9% | -1.4 | -7.2% |
| MAT | 2 081 362 | -20.9% | 6.7% | -0.7 | 852 920 462 | -12.8% | 7.2% | -0.9 | -12.7% |
| MILDRONATE | |||||||||
| WoW | 126 524 | -0.8% | 22.5% | 0.5 | 62 815 957 | 2.8% | 21.8% | 0.9 | -3.0% |
| MoM | 430 393 | 3.2% | 20.8% | -0.6 | 175 124 906 | 7.9% | 17.9% | 0 | 6.2% |
| YTD | 888 050 | 16.8% | 16.3% | 1.4 | 392 442 049 | 20.5% | 15.5% | 1.2 | 6.8% |
| MAT | 4 923 162 | 10.0% | 16.6% | 2.6 | 2 000 318 867 | 13.2% | 14.8% | 2 | -7.2% |
| SULFARGIN | |||||||||
| WoW | 3 356 | -13.1% | 1.0% | -0.1 | 1 627 973 | -11.1% | 1.3% | -0.1 | -4.0% |
| MoM | 13 779 | -21.2% | 0.9% | -0.3 | 6 745 395 | -20.1% | 1.3% | -0.3 | 4.0% |
| YTD | 26 321 | 3.0% | 1.0% | 0.1 | 12 756 179 | 7.3% | 1.3% | 0.3 | -7.8% |
| MAT | 164 922 | -20.8% | 0.8% | -0.1 | 80 623 217 | -9.2% | 1.2% | 0 | -11.5% |
| VIPROSAL | |||||||||
| WoW | 28 108 | -3.7% | 4.3% | 0 | 11 166 351 | -3.1% | 4.3% | 0 | -3.7% |
| MoM | 121 819 | -11.4% | 4.4% | -0.8 | 48 011 965 | -11.8% | 4.6% | -0.9 | 4.8% |
| YTD | 230 845 | 30.0% | 4.4% | 1.2 | 90 969 323 | 32.2% | 4.5% | 1 | -5.2% |
| MAT | 1 296 774 | -6.5% | 3.9% | 0.3 | 493 454 614 | 0.7% | 3.9% | 0.1 | -13.8% |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat.Vol, Change |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | 2 881 | -8.5% | 58.6% | 1.1 | 1 291 824 | -9.5% | 84.3% | 0.5 | -10.3% |
| CAPSICAM | 43 966 | -5.0% | 3.7% | -0.1 | 18 103 082 | -4.3% | 3.8% | -0.1 | -2.4% |
| MILDRONATE | 126 524 | -0.8% | 22.5% | 0.5 | 62 815 957 | 2.8% | 21.8% | 0.9 | -3.0% |
| SULFARGIN | 3 356 | -13.1% | 1.0% | -0.1 | 1 627 973 | -11.1% | 1.3% | -0.1 | -4.0% |
| VIPROSAL | 28 108 | -3.7% | 4.3% | 0 | 11 166 351 | -3.1% | 4.3% | 0 | -3.7% |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat.Vol, Change |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | 9 905 | 26.3% | 51.5% | 5.7 | 4 344 704 | 26.7% | 79.8% | 4 | 12.3% |
| CAPSICAM | 197 048 | -7.4% | 3.9% | -0.6 | 80 797 216 | -6.6% | 4.1% | -0.6 | 7.0% |
| MILDRONATE | 430 393 | 3.2% | 20.8% | -0.6 | 175 124 906 | 7.9% | 17.9% | 0 | 6.2% |
| SULFARGIN | 13 779 | -21.2% | 0.9% | -0.3 | 6 745 395 | -20.1% | 1.3% | -0.3 | 4.0% |
| VIPROSAL | 121 819 | -11.4% | 4.4% | -0.8 | 48 011 965 | -11.8% | 4.6% | -0.9 | 4.8% |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat.Vol, Change |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | 20 674 | 2.4% | 53.8% | -5.1 | 9 181 650 | 29.7% | 81.5% | 0.1 | 12.1% |
| CAPSICAM | 361 990 | -11.9% | 7.5% | -0.4 | 148 259 340 | -14.4% | 7.9% | -1.4 | -7.2% |
| MILDRONATE | 888 050 | 16.8% | 16.3% | 1.4 | 392 442 049 | 20.5% | 15.5% | 1.2 | 6.8% |
| SULFARGIN | 26 321 | 3.0% | 1.0% | 0.1 | 12 756 179 | 7.3% | 1.3% | 0.3 | -7.8% |
| VIPROSAL | 230 845 | 30.0% | 4.4% | 1.2 | 90 969 323 | 32.2% | 4.5% | 1 | -5.2% |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat.Vol, Change |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | 118 097 | -22.4% | 54.8% | -6.8 | 47 714 967 | 2.7% | 80.3% | -0.8 | -12.8% |
| CAPSICAM | 2 081 362 | -20.9% | 6.7% | -0.7 | 852 920 462 | -12.8% | 7.2% | -0.9 | -12.7% |
| MILDRONATE | 4 923 162 | 10.0% | 16.6% | 2.6 | 2 000 318 867 | 13.2% | 14.8% | 2 | -7.2% |
| SULFARGIN | 164 922 | -20.8% | 0.8% | -0.1 | 80 623 217 | -9.2% | 1.2% | 0 | -11.5% |
| VIPROSAL | 1 296 774 | -6.5% | 3.9% | 0.3 | 493 454 614 | 0.7% | 3.9% | 0.1 | -13.8% |
## [1] "VIPROSAL"
## [1] "VIPROSAL B UNGUENT FOR EXT USE 30 G #1"
## [1] "VIPROSAL B UNGUENT FOR EXT USE 50 G #1"
## [1] "VIPROSAL B UNGUENT FOR EXT USE 75 G #1"
## [1] "VIPROSAL"
## [1] "VIPROSAL B UNGUENT FOR EXT USE 30 G #1"
## [1] "VIPROSAL B UNGUENT FOR EXT USE 50 G #1"
## [1] "VIPROSAL B UNGUENT FOR EXT USE 75 G #1"
## [1] "CAPSICAM"
## [1] "CAPSICAM UNGUENT FOR EXT USE 30 G #1"
## [1] "CAPSICAM UNGUENT FOR EXT USE 50 G #1"
## [1] "CAPSICAM"
## [1] "CAPSICAM UNGUENT FOR EXT USE 30 G #1"
## [1] "CAPSICAM UNGUENT FOR EXT USE 50 G #1"
## [1] "MILDRONATE CAPS 500 MG #60"
## [1] "MILDRONATE CAPS 250 MG #40"
## [1] "MILDRONATE CAPS 500 MG #30"
## [1] "MILDRONATE CAPS 500 MG #60"
## [1] "MILDRONATE CAPS 500 MG #90"
## [1] "MILDRONATE CAPS 500 MG #60"
## [1] "MILDRONATE CAPS 250 MG #40"
## [1] "MILDRONATE CAPS 500 MG #30"
## [1] "MILDRONATE CAPS 500 MG #60"
## [1] "MILDRONATE CAPS 500 MG #90"
## [1] "SULFARGIN"
## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 15 G #1"
## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 50 G #1"
## [1] "SULFARGIN"
## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 15 G #1"
## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 50 G #1"
## [1] "APILAC"
## [1] "APILAC TABS 10 MG #25"
## [1] "APILAC TABS 10 MG #50"
## [1] "APILAC"
## [1] "APILAC TABS 10 MG #25"
## [1] "APILAC TABS 10 MG #50"
Abbreviations
WoW - Week Over Week Change = Sales of the last week / Sales of the previous week - 1
MoM - Month Over Month Change = Sales of the last full month / Sales of the previous full month - 1
YTD - Year to Date - a period of time beginning the first day of the current calendar year up to the current date
MAT - Moving Annual Total - a period, being any 12 month period ending on the last week
MS - Market Share
Data Sources:
DSM: Sales
Palomars: TRPs
MI: Fact Digital Costs
MI Estimated Costs: TV costs